PL3740492T3 - Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53 - Google Patents

Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53

Info

Publication number: PL3740492T3
Authority: PL; Poland
Prior art keywords: pyrrolo; spiro; indole; pyrrole; tetrahydro
Prior art date: 2018-01-16

Application number

PL19701777.5T

Other languages

English (en)

Inventor

Marcin FEDER

Maria Mazur

Iwona KALINOWSKA

Joanna JASZCZEWSKA-ADAMCZAK

Wojciech LEWANDOWSKI

Jakub WITKOWSKI

Sabina Jeleń

Katarzyna Woś-Latosi

Original Assignee

Adamed Pharma S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-01-16

Filing date

2019-01-09

Publication date

2022-08-08

2019-01-09 Application filed by Adamed Pharma S.A. filed Critical Adamed Pharma S.A.

2022-08-08 Publication of PL3740492T3 publication Critical patent/PL3740492T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL19701777.5T 2018-01-16 2019-01-09 Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53 PL3740492T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP18461506.0A EP3511334A1 (en)	2018-01-16	2018-01-16	1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53
PCT/EP2019/050370 WO2019141549A1 (en)	2018-01-16	2019-01-09	1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53

Publications (1)

Publication Number	Publication Date
PL3740492T3 true PL3740492T3 (pl)	2022-08-08

Family

ID=60997409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL19701777.5T PL3740492T3 (pl)	2018-01-16	2019-01-09	Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53

Country Status (24)

Country	Link
US (1)	US12415811B2 (pl)
EP (2)	EP3511334A1 (pl)
JP (1)	JP7284190B2 (pl)
KR (1)	KR102755407B1 (pl)
CN (1)	CN111566110B (pl)
AU (1)	AU2019209114B2 (pl)
CY (1)	CY1125134T1 (pl)
DK (1)	DK3740492T3 (pl)
EA (1)	EA202091718A1 (pl)
ES (1)	ES2911229T3 (pl)
HR (1)	HRP20220458T1 (pl)
HU (1)	HUE058461T2 (pl)
IL (1)	IL276006B2 (pl)
LT (1)	LT3740492T (pl)
MX (1)	MX2020007580A (pl)
PL (1)	PL3740492T3 (pl)
PT (1)	PT3740492T (pl)
RS (1)	RS63123B1 (pl)
SG (1)	SG11202006048PA (pl)
SI (1)	SI3740492T1 (pl)
SM (1)	SMT202200172T1 (pl)
UA (1)	UA127457C2 (pl)
WO (1)	WO2019141549A1 (pl)
ZA (1)	ZA202004972B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN119613416B (zh) *	2024-12-23	2025-11-04	聊城金歌合成材料有限公司	甲氧基螺吲哚吡咯烷酮化合物的合成方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070213341A1 (en) *	2006-03-13	2007-09-13	Li Chen	Spiroindolinone derivatives
US7834179B2 (en) *	2007-05-23	2010-11-16	Hoffmann-La Roche Inc.	Spiroindolinone derivatives
US7776875B2 (en) *	2007-12-19	2010-08-17	Hoffman-La Roche Inc.	Spiroindolinone derivatives
US7723372B2 (en) *	2008-03-19	2010-05-25	Hoffman-La Roche Inc.	Spiroindolinone derivatives
US8076482B2 (en) *	2009-04-23	2011-12-13	Hoffmann-La Roche Inc.	3,3′-spiroindolinone derivatives
US8088815B2 (en) *	2009-12-02	2012-01-03	Hoffman-La Roche Inc.	Spiroindolinone pyrrolidines
US8217044B2 (en) *	2010-04-28	2012-07-10	Hoffmann-La Roche Inc.	Spiroindolinone pyrrolidines
US20120071499A1 (en) *	2010-09-20	2012-03-22	Xin-Jie Chu	Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
MX2013005238A (es) *	2010-11-12	2013-09-02	Univ Michigan	Antagonistas de mdm2 de espiro-oxindol.
DK2684880T3 (en) *	2011-03-10	2018-05-22	Daiichi Sankyo Co Ltd	DISPIROPYRROLIDINE DERIVATIVES
BR112013028983A2 (pt) *	2011-05-11	2017-02-07	Sanofi Sa	antagonistas mdm2 espiro-oxindol
WO2013080141A1 (en) *	2011-11-29	2013-06-06	Novartis Ag	Pyrazolopyrrolidine compounds
US8815926B2 (en) *	2012-01-26	2014-08-26	Novartis Ag	Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
MX373045B (es) *	2014-04-17	2020-05-26	Univ Michigan Regents	Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
JP2017517555A (ja)	2014-06-12	2017-06-29	アダムドエスピー．ゼットオー．オー．ＡｄａｍｅｄＳｐ．ＺＯ．Ｏ．	阻害剤ｐ５３−Ｍｄｍ２タンパク質−タンパク質相互作用としての、１，１’，２，５’−テトラヒドロスピロ［インドール−３，２’−ピロール］−２，５’−ジオン系を含む化合物
JP6503386B2 (ja) *	2014-07-03	2019-04-17	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
ES2959097T3 (es) *	2014-08-18	2024-02-20	Hudson Biopharma Inc	Espiropirrolidinas como inhibidores de MDM2
MX373033B (es) *	2014-08-21	2020-05-27	Boehringer Ingelheim Int	Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53.
EP3359542B1 (en) *	2015-10-09	2021-03-17	Boehringer Ingelheim International GmbH	Spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
CN105585570B (zh) *	2015-12-15	2019-10-15	贵州大学	异恶唑拼接吡咯螺环氧化吲哚化合物及其制备方法及应用
CN105669683B (zh) *	2015-12-28	2020-06-16	徐州医学院	一类吲哚螺吡咯衍生物的合成及其作为肿瘤治疗药物的应用
CN106008532B (zh) *	2016-07-20	2019-06-07	贵州大学	烷氧基嘧啶拼接3-吡咯螺环氧化吲哚衍生物及其制备方法及应用

2018
- 2018-01-16 EP EP18461506.0A patent/EP3511334A1/en not_active Withdrawn
2019
- 2019-01-09 HR HRP20220458TT patent/HRP20220458T1/hr unknown
- 2019-01-09 SG SG11202006048PA patent/SG11202006048PA/en unknown
- 2019-01-09 ES ES19701777T patent/ES2911229T3/es active Active
- 2019-01-09 WO PCT/EP2019/050370 patent/WO2019141549A1/en not_active Ceased
- 2019-01-09 PT PT197017775T patent/PT3740492T/pt unknown
- 2019-01-09 UA UAA202004497A patent/UA127457C2/uk unknown
- 2019-01-09 US US16/962,647 patent/US12415811B2/en active Active
- 2019-01-09 CN CN201980007138.5A patent/CN111566110B/zh active Active
- 2019-01-09 RS RS20220326A patent/RS63123B1/sr unknown
- 2019-01-09 LT LTEPPCT/EP2019/050370T patent/LT3740492T/lt unknown
- 2019-01-09 MX MX2020007580A patent/MX2020007580A/es unknown
- 2019-01-09 PL PL19701777.5T patent/PL3740492T3/pl unknown
- 2019-01-09 DK DK19701777.5T patent/DK3740492T3/da active
- 2019-01-09 EP EP19701777.5A patent/EP3740492B1/en active Active
- 2019-01-09 JP JP2020559015A patent/JP7284190B2/ja active Active
- 2019-01-09 SI SI201930201T patent/SI3740492T1/sl unknown
- 2019-01-09 HU HUE19701777A patent/HUE058461T2/hu unknown
- 2019-01-09 AU AU2019209114A patent/AU2019209114B2/en active Active
- 2019-01-09 EA EA202091718A patent/EA202091718A1/ru unknown
- 2019-01-09 KR KR1020207020046A patent/KR102755407B1/ko active Active
- 2019-01-09 SM SM20220172T patent/SMT202200172T1/it unknown
2020
- 2020-07-13 IL IL276006A patent/IL276006B2/en unknown
- 2020-08-12 ZA ZA2020/04972A patent/ZA202004972B/en unknown
2022
- 2022-04-05 CY CY20221100257T patent/CY1125134T1/el unknown

Also Published As

Publication number	Publication date
MX2020007580A (es)	2020-11-18
CN111566110A (zh)	2020-08-21
CN111566110B (zh)	2023-04-25
LT3740492T (lt)	2022-05-10
RS63123B1 (sr)	2022-05-31
SI3740492T1 (sl)	2022-05-31
EP3740492B1 (en)	2022-03-02
KR20200110322A (ko)	2020-09-23
US20200354372A1 (en)	2020-11-12
KR102755407B1 (ko)	2025-01-20
BR112020014427A2 (pt)	2020-12-01
EP3511334A1 (en)	2019-07-17
UA127457C2 (uk)	2023-08-30
AU2019209114A1 (en)	2020-07-09
SG11202006048PA (en)	2020-08-28
WO2019141549A1 (en)	2019-07-25
JP2021512141A (ja)	2021-05-13
WO2019141549A9 (en)	2019-10-10
IL276006B (en)	2022-11-01
ZA202004972B (en)	2021-08-25
PT3740492T (pt)	2022-04-13
CY1125134T1 (el)	2024-02-16
CA3086440A1 (en)	2019-07-25
JP7284190B2 (ja)	2023-05-30
US12415811B2 (en)	2025-09-16
HUE058461T2 (hu)	2023-09-28
NZ765577A (en)	2024-10-25
IL276006B2 (en)	2023-03-01
AU2019209114B2 (en)	2022-12-08
IL276006A (en)	2020-08-31
DK3740492T3 (da)	2022-04-19
HRP20220458T1 (hr)	2022-05-27
EA202091718A1 (ru)	2020-10-27
ES2911229T3 (es)	2022-05-18
SMT202200172T1 (it)	2022-05-12
EP3740492A1 (en)	2020-11-25

Publication	Publication Date	Title
DOP2018000263A (es)	2019-03-31	Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4
IL281719B (en)	2022-06-01	4'-phenyl-2-oxospiro]indoline-3,3'-pyrrolidine]-5' carboxamide derivatives as mdm2 protein complexes
AR110368A1 (es)	2019-03-20	Inhibidores de la rip1 cinasa y métodos y uso de éstos
NZ751509A (en)	2023-03-31	Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
JP2011500774A5 (pl)	2011-12-15
IL280513A (en)	2021-03-01	Imidazo[2,1-B]pyridazines as TRK inhibitors
CL2009001158A1 (es)	2009-10-23	Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
PL3740492T3 (pl)	2022-08-08	Związki 1,2,3’,5’‐tetrahydro‐2’H‐spiro[indolo‐3,1’‐pirolo[3,4‐c]pirolo]‐2,3’‐dionowe jako środki terapeutyczne aktywujące TP53
IL280122A (en)	2021-03-01	Imidazo[2,1-B]pyridazine derivatives as TRK inhibitors
PH12016502271B1 (en)	2017-02-06	Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014193881A8 (en)	2016-04-07	Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
MX2025012362A (es)	2025-11-03	Derivados de 1,6-naftiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4, utiles para el tratamiento de trastornos neurologicos y psiquiatricos
WO2015145333A8 (en)	2015-11-26	Process for the preparation of sitagliptin and its intermediate
MX2025012360A (es)	2025-11-03	Derivados de pirrolopiridina como moduladores alostericos positivos del receptor muscarinico de acetilcolina m4